RedHill Biopharma (RDHL) Total Current Liabilities (2014 - 2025)

RedHill Biopharma (RDHL) has reported Total Current Liabilities for 12 consecutive years, with $19.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 13.51% year-over-year to $19.2 million in Q4 2025; TTM through Dec 2025 was $19.2 million, a 13.51% decrease from a year earlier, with the FY2025 full-year figure at $19.2 million, down 13.51% from the prior year.
• Total Current Liabilities was $19.2 million for Q4 2025 at RedHill Biopharma, down from $22.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $197.5 million in Q4 2022 and troughed at $19.2 million in Q4 2025.
• A 5-year average of $65.8 million and a median of $25.2 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 142.36% in 2022 and sank 89.88% in 2023, its largest moves.
• Over 5 years, Total Current Liabilities stood at $81.5 million in 2021, then surged by 142.36% to $197.5 million in 2022, then slumped by 89.88% to $20.0 million in 2023, then rose by 11.21% to $22.2 million in 2024, then slipped by 13.51% to $19.2 million in 2025.
• The last three Total Current Liabilities figures came in at $19.2 million (Q4 2025), $22.3 million (Q2 2025), and $22.2 million (Q4 2024), per Business Quant data.